Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Netakimab versus placebo in Chinese adults with active ankylosing spondylitis
ChiCTR2300067305Phase 3Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of netakimab in ankylosing spondylitis (AS) (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Proportion of patients reaching ASAS20. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
netakimab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on ChiCTR2300067305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300067305.